---
title: "Weekly Recap | Amgen +2.94%, MariTide buzz lifts shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301464339.md"
description: "Amgen (AMGN) finished the week up 2.94% at $414.87, beating the S&P 500 by roughly 1.79 percentage points. The stock started at $399.03 on Monday and moved higher in a choppy pattern: it dipped to $396.01 on Tuesday, jumped 3.06% on Wednesday to $413.08, pulled back to $407.44 on Thursday, then rallied to an intraday high of $417.78 on Friday before closing at $414.87. Weekly amplitude was 5.46%, with average daily volume running about 4.29% below the recent median."
datetime: "2026-10-10T06:02:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301464339.md)
  - [en](https://longbridge.com/en/news/301464339.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301464339.md)
generator: "portal-rs"
---

# Weekly Recap | Amgen +2.94%, MariTide buzz lifts shares

## The Week

Amgen (AMGN) finished the week up 2.94% at $414.87, beating the S&P 500 by roughly 1.79 percentage points. The stock started at $399.03 on Monday and moved higher in a choppy pattern: it dipped to $396.01 on Tuesday, jumped 3.06% on Wednesday to $413.08, pulled back to $407.44 on Thursday, then rallied to an intraday high of $417.78 on Friday before closing at $414.87. Weekly amplitude was 5.46%, with average daily volume running about 4.29% below the recent median.

## Key Events

The MariTide obesity candidate drove much of this week’s narrative. Amgen’s 3.06% rise on Wednesday was followed by analysis arguing the MariTide buzz is testing whether the stock is already fully valued. An English-language piece framed pipeline wins and MariTide Phase 3 advancement as strengthening the growth story. Wednesday’s broad market sell-off knocked the Dow down over 500 points, and Amgen’s decline alongside Johnson & Johnson dragged the Dow nearly 150 points, though Amgen still outperformed most peers during Thursday’s strong session. Cantor Fitzgerald initiated coverage with a hold rating. Amgen also appeared among healthcare names with high EPS revision grades ahead of Q3 results.

## Analyst Ratings

Among 34 firms covering Amgen, 8 rate it buy, 4 rate it overweight, 17 rate it hold, 2 rate it underweight, and 3 rate it sell; the consensus is hold. The consensus target sits at $395.25, about 4.73% below the latest price. Targets range from $225 to $500, showing wide dispersion. Amgen ranks second among 508 companies in the biotechnology industry.

## The Week Ahead

A busy macro calendar starts Tuesday with NFIB small business optimism and existing home sales data. Wednesday brings CPI and core CPI prints: core CPI is forecast at 2.5% versus a prior 2.4%, and CPI is forecast at 3.7% versus a prior 3.4%. Amgen’s own Q3 results land after the close on 3 November, with an estimated EPS of $4.0642 and revenue of about $10 billion.

## In Short

This week’s gain tracked the MariTide narrative, but the analyst consensus remains hold and the consensus target is 4.73% below spot, with high and low targets more than doubling apart. The latest session showed large-lot flow roughly balanced while medium and small orders skewed net buying. The next signals are next week’s inflation data and whether November’s earnings report can give the MariTide story more substance.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial](https://longbridge.com/en/news/302425900.md)
- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [These Analysts Revise Their Forecasts On Texas Instruments Following Q3 Results](https://longbridge.com/en/news/302755837.md)
- [GE Vernova Stock Is Taking a Hit – What's Driving the Selloff and What Wall Street Sees Next](https://longbridge.com/en/news/302747785.md)
- [Micron announces a new profit-sharing program](https://longbridge.com/en/news/302750416.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**